List of works - Roy M Gulick

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

scientific article published in July 2000

A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care

scientific article

A comparison of three initial antiretroviral AIDS regimens

scientific article published on 01 September 2007

A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

scientific article published on 27 June 2012

A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.

scientific article

ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.

scientific article

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).

scientific article published on 24 May 2005

Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.

scientific article

Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy

scientific article published on 01 December 2002

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

scientific article

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens

scientific article

Antiretroviral therapy in a thousand patients with AIDS in Haiti

scientific article

Antiretroviral therapy: when and what to start-- an American perspective

scientific article

Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions

scientific article published on 3 June 2009

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

scientific article

Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve

scientific article published on 20 November 2020

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events

scientific article published on 01 July 2018

Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients

scientific article published in April 2003

CCR5 antagonism in HIV infection: current concepts and future opportunities

scientific article

COVID-19 in Hospitalized Adults With HIV

scientific article published on 01 August 2020

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

scientific article published on 01 August 2021

Case-control study of diabetes mellitus in HIV-infected patients

scientific article

Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals

scientific article

Clinical Characteristics of Covid-19 in New York City

scientific article published on 17 April 2020

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

scientific article published in Nature

Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy

scientific article published on 01 August 2019

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study

scientific article

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884

scientific article published on 01 November 2000

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

scientific article published on 25 September 2020

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial ⬇️

journal article from 'Nature Medicine' published in 2021

Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

scientific article published on 23 March 2016

Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City

scientific article published on 27 August 2015

Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development ⬇️

scientific article published on January 1, 2012

Design issues in initial HIV-treatment trials: focus on ACTG A5095.

scientific article published in January 2006

Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19

scientific article published in 2021

Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists ⬇️

scientific article published on January 17, 2012

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353

scientific article published in 2019

Drug Costs: What Can Infectious Diseases Physicians Do?

scientific article published on 01 February 2020

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

scientific article published in July 2002

Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

scientific article published on 9 August 2002

Early versus standard antiretroviral therapy for HIV-infected adults in Haiti

scientific article published on July 2010

Efavirenz Pharmacogenetics and Weight Gain following Switch to Integrase Inhibitor-containing Regimens

scientific article published on 23 August 2020

Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts

scientific article published in April 2008

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

scientific article

Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure ⬇️

scientific article published on February 24, 2011

Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095 ⬇️

scientific article published on July 24, 2012

Evidence of Ongoing Immune Reconstitution in Subjects with Sustained Viral Suppression following 6 Years of Lopinavir-Ritonavir Treatment

article

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients

scientific article published on January 2014

Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.

scientific article

Genetic Variation of the Kinases that Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells

scientific article published on 17 February 2018

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study

scientific article

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

scientific article published on December 2012

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols

scientific article

Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection

scientific article

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

scientific article published on 17 January 2007

HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug ⬇️

scientific article published on November 16, 2011

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

scientific article

Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus

scientific article published on 2 November 2005

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

scientific article

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject

scientific article published on 21 May 2008

Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.

scientific article

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression

scientific article published on April 2007

Invasive Meningococcal Disease in Men Who Have Sex With Men ⬇️

scientific article published on August 20, 2013

Long-Acting HIV Drugs for Treatment and Prevention

article

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

scientific article

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

scientific article published in March 2004

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

scientific article published on March 2009

Maraviroc for previously treated patients with R5 HIV-1 infection

scientific article

Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.

scientific article

Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)

scientific article published on 01 April 2007

Modeling Clinical Endpoints as a Function of Time of Switch to Second‐Line ART with Incomplete Data on Switching Times ⬇️

scientific article published on July 17, 2013

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

scientific article published in PLoS ONE

Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.

scientific article published in March 2007

Obesity and COVID-19 in New York City: A Retrospective Cohort Study

scientific article published on 06 July 2020

Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions

scientific article published on 01 March 2019

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

scientific article published in December 2004

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

scientific article published on 27 December 2005

Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases ⬇️

scientific article published on September 1, 2011

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).

scientific article

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).

scientific article published on 2 November 2016

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

scientific article published on 05 June 2007

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols

scientific article

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s

scientific article published on 06 March 2007

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure

scientific article

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects

scientific article published in March 2008

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy

scientific article published on 09 March 2020

Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects

scientific article

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo

scientific article

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

scientific article published on September 2017

Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy

article

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis

scientific article published on 17 September 2013

Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.

scientific article

Raltegravir: the first HIV type 1 integrase inhibitor

scientific article (publication date: April 2009)

Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment

scientific article published on 01 January 2021

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.

scientific article published on 9 October 2000

Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity ⬇️

scientific article published on April 1, 2011

Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.

scientific article published on May 2014

Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117

article

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211

scientific article

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial

scientific article published on 22 August 2017

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

scientific article published on 14 February 2002

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

article

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

scientific article published on 23 July 2020

Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients

scientific article published in January 2008

Severe Covid-19

scientific article published on 15 May 2020

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

scientific article published on 16 March 2004

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

scientific article published on 2 March 2004

Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection ⬇️

scientific article published on July 1, 1998

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine ⬇️

scientific article published on November 7, 2003

Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095

scientific article

Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals

scientific article published on December 2008

Switching antiretroviral therapy: why, when and how

scientific article published on 01 July 2006

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies

scientific article published on 01 November 2018

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

scientific article published on 9 December 2015

The Uncertain Role of Corticosteroids in the Treatment of COVID-19

scientific article published on 03 August 2020

The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).

scientific article

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

scientific article

The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects

scientific article

The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).

scientific article published on 26 June 2002

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM

scientific article published on 01 February 2019

The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients

scientific article

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

scientific article published on August 2006

Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients ⬇️

scientific article published on August 1, 2010

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

scientific article published on 26 April 2021

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

scientific article

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

scientific article published in September 1997

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

scientific article published on April 2004

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

scientific article published in December 2010

Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants ⬇️

scientific article published on January 1, 2011

Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates under Sequential Drug Selection Pressures ⬇️

scientific article published on April 4, 2012

Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.

scientific article

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

scientific article published on 08 April 2015

Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery

scientific article

Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti

scientific article

Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.

scientific article

When to start antiretroviral therapy?

scientific article published on December 2008

List of works by Roy M Gulick

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care

A comparison of three initial antiretroviral AIDS regimens

A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.

ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).

Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.

Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens

Antiretroviral therapy in a thousand patients with AIDS in Haiti

Antiretroviral therapy: when and what to start-- an American perspective

Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events

Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients

CCR5 antagonism in HIV infection: current concepts and future opportunities

COVID-19 in Hospitalized Adults With HIV

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Case-control study of diabetes mellitus in HIV-infected patients

Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals

Clinical Characteristics of Covid-19 in New York City

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial ⬇️

Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City

Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development ⬇️

Design issues in initial HIV-treatment trials: focus on ACTG A5095.

Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19

Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists ⬇️

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353

Drug Costs: What Can Infectious Diseases Physicians Do?

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

Early versus standard antiretroviral therapy for HIV-infected adults in Haiti

Efavirenz Pharmacogenetics and Weight Gain following Switch to Integrase Inhibitor-containing Regimens

Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure ⬇️

Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095 ⬇️

Evidence of Ongoing Immune Reconstitution in Subjects with Sustained Viral Suppression following 6 Years of Lopinavir-Ritonavir Treatment

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients

Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.

Genetic Variation of the Kinases that Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols

Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug ⬇️

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject

Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression

Invasive Meningococcal Disease in Men Who Have Sex With Men ⬇️

Long-Acting HIV Drugs for Treatment and Prevention

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

Maraviroc for previously treated patients with R5 HIV-1 infection

Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.

Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)

Modeling Clinical Endpoints as a Function of Time of Switch to Second‐Line ART with Incomplete Data on Switching Times ⬇️

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.

Obesity and COVID-19 in New York City: A Retrospective Cohort Study

Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases ⬇️

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).